ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
暂无分享,去创建一个
Jeffrey S. Morris | J. Ajani | J. Shen | S. Kopetz | M. Overman | G. Manyam | J. Roszik | D. Maru | J. Willis | J. Loree | Jennifer S. Davis | S. Advani | Hey Min Lee | Michael Lam | R. Katkhuda | Amir Mehrvarz Sarshekeh | A. Verma | Jumanah Alshenaifi | H. Lee
[1] V. Balis,et al. Diagnostic significance and prognostic role of the ARID1A gene in cancer outcomes (Review) , 2020 .
[2] Kathleen R. Cho,et al. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. , 2020, The Journal of clinical investigation.
[3] Mei Jiang,et al. Procedural Requirements and Recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification Assays to Support Translational Oncology Studies , 2020, Cancers.
[4] T. Jiang,et al. Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes , 2020, Journal of Cancer.
[5] C. Röcken,et al. Intratumoral heterogeneity and loss of ARID1A expression in gastric cancer correlates with increased PD-L1 expression in Western patients. , 2019, Human pathology.
[6] Jeffrey H. Chuang,et al. Clinical and immunological implications of frameshift mutations in lung cancer. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] Xiaosheng Wang,et al. ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer , 2019, Cells.
[8] Z. Stadler,et al. Immunotherapy in colorectal cancer: rationale, challenges and potential , 2019, Nature Reviews Gastroenterology & Hepatology.
[9] M. Szewczuk,et al. Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates , 2019, Journal of oncology.
[10] Dakeun Lee,et al. Functional loss of ARID1A is tightly associated with high PD‐L1 expression in gastric cancer , 2019, International journal of cancer.
[11] P. Ulivi,et al. Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine? , 2018, International journal of molecular sciences.
[12] T A Chan,et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[14] F. Meric-Bernstam,et al. The characteristics of ARID1A mutations in colorectal cancer. , 2018 .
[15] G. Mills,et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade , 2018, Nature Medicine.
[16] L. Macconaill,et al. Frameshift events predict anti-PD-1/L1 response in head and neck cancer. , 2018, JCI insight.
[17] Ritika Kundra,et al. Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. , 2018, Cancer cell.
[18] I. Wistuba,et al. Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues , 2017, Scientific Reports.
[19] Nicolai J. Birkbak,et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. , 2017, The Lancet. Oncology.
[20] A. Jazaeri,et al. Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators , 2017, Front. Immunol..
[21] Robyn L. Temple-Smolkin,et al. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. Park,et al. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice , 2016, Nature Genetics.
[23] Eric S. Lander,et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma , 2016, Cell reports.
[24] Jeffrey S. Morris,et al. The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.
[25] R. Xu,et al. Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. , 2014, World journal of gastroenterology.
[26] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[27] Chichung Wang,et al. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. , 2014, Methods.
[28] Kai Ye,et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data , 2014, Bioinform..
[29] Tian-Li Wang,et al. The emerging roles of ARID1A in tumor suppression , 2014, Cancer biology & therapy.
[30] B. Clarke,et al. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas , 2014, Modern Pathology.
[31] Swe Swe Myint,et al. Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers , 2013, Nature Genetics.
[32] Mauricio O. Carneiro,et al. From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.
[33] H. Morreau,et al. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer , 2013, Modern Pathology.
[34] Jeffrey J Meyer,et al. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012. (5) , 2013 .
[35] Jonathan R. Pollack,et al. The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers , 2013, PloS one.
[36] D. Reisman,et al. Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity. , 2012, Experimental cell research.
[37] S. Ishikawa,et al. ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein–Barr virus infection and microsatellite instability , 2012, Virchows Archiv.
[38] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[39] Guangchuang Yu,et al. clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.
[40] Bin Tean Teh,et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes , 2012, Nature Genetics.
[41] Zhengyan Kan,et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer , 2011, Nature Genetics.
[42] Tian-Li Wang,et al. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. , 2011, Cancer research.
[43] Meng Li,et al. Somatic Mutations in the Chromatin Remodeling Gene ARID1A Occur in Several Tumor Types , 2011, Human mutation.
[44] Tian-Li Wang,et al. Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.
[45] So-jung Kim,et al. A cooperative activation loop among SWI/SNF, γ‐H2AX and H3 acetylation for DNA double‐strand break repair , 2010, The EMBO journal.
[46] G. Wani,et al. Modulation of Nucleotide Excision Repair by Mammalian SWI/SNF Chromatin-remodeling Complex* , 2009, The Journal of Biological Chemistry.
[47] B. Cairns,et al. The biology of chromatin remodeling complexes. , 2009, Annual review of biochemistry.
[48] Weidong Wang,et al. Role of the mammalian SWI/SNF chromatin remodeling complex in the cellular response to UV damage , 2008, Cell cycle.
[49] Yu Li,et al. Genomic and functional evidence for an ARID1A tumor suppressor role , 2007, Genes, chromosomes & cancer.
[50] A. Imbalzano,et al. Mammalian SWI/SNF complexes facilitate DNA double‐strand break repair by promoting γ‐H2AX induction , 2006, The EMBO journal.
[51] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[52] P. Dallas,et al. Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors , 2004, International journal of cancer.
[53] S Srivastava,et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.
[54] J. Lunceford,et al. IFN-g – related mRNA profile predicts clinical response to PD-1 blockade , 2019 .
[55] C. Roberts,et al. ARID1A mutations in cancer: another epigenetic tumor suppressor? , 2013, Cancer discovery.